Alginate-based Reflux Suppressant and Magnesium-aluminium Antacid Gel for Treatment of Heartburn in Pregnancy
Launched by CHULALONGKORN UNIVERSITY · Jun 9, 2015
Trial Information
Current as of May 17, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Pregnant women gestational age less than 36 weeks with heartburn
- Exclusion Criteria:
- • Having medical disease that contraindicated to use study drug
- • Allergic to alginate-based reflux suppressant and magnesium-aluminium antacid gel
About Chulalongkorn University
Chulalongkorn University, one of Thailand's premier academic institutions, is dedicated to advancing medical research and enhancing healthcare outcomes through innovative clinical trials. With a strong emphasis on collaboration and interdisciplinary approaches, the university leverages its extensive resources and expertise in various medical fields to conduct rigorous scientific investigations. Chulalongkorn University aims to contribute to global health advancements by fostering a culture of excellence in research, education, and community service, ultimately improving patient care and public health standards.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bangkok, , Thailand
Patients applied
Trial Officials
Vorapong Phupong, M.D.
Study Director
Chulalongkorn University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials